U.K. biotech Immunocore has reported an estimated 70% two-year survival rate among 17 evaluable first-line metastatic uveal melanoma patients given its experimental drug brenetafusp alongside approved Kimmtrak (tebentafusp), supporting plans for a randomized Phase 2/3 trial.